Education
About Us
Working with TipRanks
Follow Us
CareDx Inc (CDNA)
:CDNA
CDNA Stock Chart & Stats
$15.01
$0.67(2.95%)
At close: 4:00 PM EST
$15.01
$0.67(2.95%)
Day’s Range― - ―
52-Week Range$10.96 - $26.37
Previous CloseN/A
Volume177.07K
Average Volume (3M)1.19M
Market Cap
$858.93M
Enterprise Value$614.76M
Total Cash (Recent Filing)$194.22M
Total Debt (Recent Filing)$27.64M
Price to Earnings (P/E)14.1
Beta1.41
Next Earnings
Mar 04, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding51,432,640
10 Day Avg. Volume1,490,882
30 Day Avg. Volume1,192,782
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)2.99
Price to Sales (P/S)3.39
P/FCF Ratio35.80
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue1.72
Enterprise Value/Gross Profit2.55
Enterprise Value/Ebitda-35.80
Forecast
1Y Price Target
$22.00Price Target Upside46.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformanceTotal revenue was $100.1M, representing 20.7% YoY growth and beating our projection of $95.3M.
Operational ConfidenceThe stock is considered oversold, with shares trading below historical peer multiples, suggesting potential for a bounce-back.
Revenue GuidanceManagement has raised FY2025 revenue guidance to $372-376M, with adjusted EBITDA of $35-39M.
Bears Say
Business PressuresCareDx has seen significant business pressures, including reimbursement headaches, patent litigation, securities investigations, and changes in the executive suite.
Regulatory UncertaintyThe draft LCD from MolDX is still an overhang, and it may be resolved in 1Q26.
Testing Services ImpactA recently proposed local coverage decision impacting the testing services segment clouds the near-term thesis.
CareDx News
CDNA FAQ
What was CareDx Inc’s price range in the past 12 months?
CareDx Inc lowest stock price was $10.96 and its highest was $26.37 in the past 12 months.
What is CareDx Inc’s market cap?
CareDx Inc’s market cap is $858.93M.
When is CareDx Inc’s upcoming earnings report date?
CareDx Inc’s upcoming earnings report date is Mar 04, 2026 which is in 111 days.
How were CareDx Inc’s earnings last quarter?
CareDx Inc released its earnings results on Nov 04, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of -$0.082 by $0.112.
Is CareDx Inc overvalued?
According to Wall Street analysts CareDx Inc’s price is currently Undervalued.
Does CareDx Inc pay dividends?
CareDx Inc does not currently pay dividends.
What is CareDx Inc’s EPS estimate?
CareDx Inc’s EPS estimate is -0.01.
How many shares outstanding does CareDx Inc have?
CareDx Inc has 51,432,640 shares outstanding.
What happened to CareDx Inc’s price movement after its last earnings report?
CareDx Inc reported an EPS of $0.03 in its last earnings report, beating expectations of -$0.082. Following the earnings report the stock price went up 13.843%.
Which hedge fund is a major shareholder of CareDx Inc?
Currently, no hedge funds are holding shares in CDNA
CareDx Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$22.00 (46.57% Upside)
$22.00 (46.57% Upside)
Blogger Sentiment
Neutral
CDNA Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 417.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 8.2%
Last 30 Days ▼ 12.1%
Last 30 Days ▼ 12.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.10%
12-Months-Change
Fundamentals
Return on Equity
24.11%
Trailing 12-Months
Asset Growth
-9.37%
Trailing 12-Months
Company Description
CareDx Inc
CareDx, Inc. is a leading precision medicine company focused on transplant medicine, specializing in developing and providing diagnostic solutions for organ transplant patients. The company operates primarily in the healthcare sector, offering products and services that enhance patient care and improve transplant outcomes. CareDx's core products include AlloSure, a non-invasive blood test that assesses kidney transplant rejection, and AlloMap, a gene expression profiling test used to monitor heart transplant patients.
CDNA Company Deck
CDNA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong quarter with significant revenue growth and operational improvements, including successful product launches and strategic initiatives. However, the overall market conditions for transplant volumes have been flat, and the expected impact from the IOTA program has not yet been realized.View all CDNA earnings summariesCDNA Stock 12 Month Forecast
Average Price Target
$22.00
▲(46.57% Upside)
Technical Analysis
Ownership Overview
9.19% Insiders
26.97% Mutual Funds
0.25% Other Institutional Investors
42.96% Public Companies and
Individual Investors